

## **ADA 2020 SYMPOSIUM (RP2006A)**

### **Disclosure Of Commercial Interest**

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), The University of Texas Southwestern Medical Center, Office of Continuing Medical Education (UTSW CME) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of a commercial entity and promote improvements or quality in healthcare. All persons in the position to control the content of an education activity are required to disclose all relevant financial relationships in any amount occurring within the past 12 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients.

The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The UTSW Office of CME has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity. The intent of this policy is to identify potential conflicts of interest so participants can form their own judgments with full disclosure of the facts. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity.

<b>Faculty</b>	<b>Relationship</b>	<b>Company</b>
Jaime A. Davidson, MD, FACP, MACE (Course Director)	Advisor	AspireBariatrics, AstraZeneca, Merck Sharp & Dohme, Merck-Serono LA
	Consultant	Aspire Bariatrics, Pancreate, Valeritas
	Ownership Interest	Aspire Bariatrics, Boston Pharmaceuticals
Yulino Castillo Núñez MD	Speaker	AstraZeneca, Merck Sharp & Dohme, Novo Nordisk
Roque Cardona-Hernandez, MD	Advisor	Abbott, Dexcom-AirLiquide, Eli Lilly, Medtronic, Novo-Nordisk, Sanofi Aventis
	Research	Eli Lilly, Novo-Nordisk, Sanofi-Aventis
Rodolfo J. Galindo, MD, FACE	Research	Novo Nordisk
	Consultant	Abbott, Eli Lilly, Novo Nordisk, Sanofi, Valeritas
	Ownership Interest	EMIS
Jorge H. Mestman, MD (Peer Reviewer)	None	
<b>Planning Committee</b>		
Ruben Gutierrez Sergio Salamanca Jane Savio Mark Vinciguerra	None	

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians’ Desk Reference.

This symposium has been planned to be well-balanced and objective in discussion of comparative treatment regimens, and the symposium format allows for the free scientific exchange of ideas. Information and opinions offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.